Fundamental analysis · SEC EDGAR · TTM through 30/06/2026
MRNA · Nasdaq · Healthcare
Fundamental quality
56
out of 100
Moderna, Inc. is in full growth mode but not yet profitable: revenue is growing strongly (20.4% a year), but it doesn't translate into earnings yet. On fundamental quality it scores 56 out of 100, profiling it as a company of reasonable quality. Its weakest area is its profitability (net margin -141.4%). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
Moderna is the messenger-RNA company: its covid vaccine made it a giant overnight, and it has since been trying to prove that technology works for much more — flu, respiratory viruses and above all personalized cancer vaccines.
Revenue growth: 20.4%
Net margin: -141.4% · ROE: -46.6%
Net debt/EBITDA: 0.37x · FCF: -55.8%
Source: SEC EDGAR · TTM through 30/06/2026
The score combines growth, profitability and financial strength. Here its growth weighs in its favor, while its profitability drags it down the most.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2020 | 803 | -747 | 1,959 | -2,624 |
| 2021 | 18,471 | 12,202 | 13,336 | -6,848 |
| 2022 | 19,263 | 8,362 | 4,581 | -3,205 |
| 2023 | 6,848 | -4,714 | -3,825 | -2,907 |
| 2024 | 3,236 | -3,561 | -4,055 | -1,927 |
| 2025 | 1,944 | -2,822 | -2,065 | -2,005 |
Between 2020 and 2025, revenue went from $803M to $1,944M (+142%) and net income went from -$747M to -$2,822M (-278%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Latest results
Figures for the half-year ended June 30, 2026, versus the half-year ended June 30, 2025 (SEC filings):
Compared with the previous close (March 31, 2026), this is what moved in its accounts:
Automatic comparison between the two most recent periods filed with the SEC. One quarter doesn't make a trend: read it alongside the historical evolution above.
This company doesn't pay a dividend: it reinvests all its earnings back into the business.
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is Moderna, Inc. cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is Moderna, Inc. a good company to invest in?
In terms of business quality, Moderna, Inc. scores 56 out of 100 in our analysis, placing it as a company of reasonable quality. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is Moderna, Inc. a profitable company?
Over the last twelve months, no: Moderna, Inc. posts a negative net margin (-141.4%).
Does Moderna, Inc. have a lot of debt?
Not particularly. Its net debt is 0.37 times its EBITDA, a low level.
Is Moderna, Inc. growing?
Its revenue has grown 20.4% annualized in recent years.
Does Moderna, Inc. generate cash?
Over the last twelve months its free cash flow was negative.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
Biogen (BIIB) · Illumina (ILMN) · Zimmer Biomet (ZBH) · Baxter International (BAX) · Cardinal Health (CAH) · Cencora (COR) · see more →
Who's behind the methodology and model · how the score is computed
Data: see Moderna, Inc.'s filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.